← Browse by Condition
Medical Condition
glioblastoma idh wildtype
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 3, Phase 2
ClinicalMetric tracks all active clinical trials for glioblastoma idh wildtype sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — glioblastoma idh wildtype Clinical Trials
How many clinical trials are currently recruiting for glioblastoma idh wildtype?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for glioblastoma idh wildtype, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for glioblastoma idh wildtype?
glioblastoma idh wildtype research spans Phase 1 (3 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a glioblastoma idh wildtype clinical trial?
Eligibility criteria for glioblastoma idh wildtype trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 2
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06283927
Recruiting
Enrollment
464 pts
Location
United States, Belgi...
Sponsor
Jasper Gerritsen
NCT07089641 Phase 1
Recruiting
Enrollment
50 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT05326334
Recruiting
Enrollment
20 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti...
NCT07223034 Phase 1
Recruiting
Enrollment
20 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06419946 Phase 3
Recruiting
Enrollment
200 pts
Location
Austria, Denmark, No...
Sponsor
Vastra Gotaland Region
NCT04945148 Phase 2
Recruiting
Enrollment
640 pts
Location
France, Italy
Sponsor
Hopital Foch
NCT06047379 Phase 1, Phase 2
Recruiting
Enrollment
134 pts
Location
United States
Sponsor
Neonc Technologies, Inc.
Related Conditions
glioblastoma (2) glioblastoma multiforme (1) glioblastoma multiforme of brain (1) glioblastoma multiforme adult (1) recurrent glioblastoma (1) astrocytoma malignant (1) astrocytoma of brain (1) gliosarcoma (1) recurrent glioblastoma idh wildtype (1) recurrent gliosarcoma (1) resectable glioblastoma (1) glioma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology